Hengrui Pharmaceutical announced that emaxitinib sulfate tablets, a Class 1 innovative drug independently developed by the company, were approved by the State Drug Administration for a fifth additional indication. It is suitable for adult patients with active radiologic negative axial spondyloarthritis who have poor response or intolerance to nonsteroidal anti-inflammatory drugs and have objective inflammatory signs. The product has previously been approved for four indications, and after this approval, oral targeted management coverage of the entire disease spectrum of axial spondyloarthritis has been achieved. Up to now, the total R&D investment for related projects is about 1,235 billion yuan.

Hengrui Pharmaceutical announced that emaxitinib sulfate tablets, a Class 1 innovative drug independently developed by the company, were approved by the State Drug Administration for a fifth additional indication. It is suitable for adult patients with active radiologic negative axial spondyloarthritis who have poor response or intolerance to nonsteroidal anti-inflammatory drugs and have objective inflammatory signs. The product has previously been approved for four indications, and after this approval, oral targeted management coverage of the entire disease spectrum of axial spondyloarthritis has been achieved. Up to now, the total R&D investment for related projects is about 1,235 billion yuan.